NCT01839552

An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.

An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids.

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Louisville · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is used to manage breakthrough pain in adults with cancer who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Lazanda is started only after taking other opioid pain medicines and the patient's body has become used to them (opioid tolerant). The purpose of this study is to assess the ability of Lazanda to control pain during an episode of breakthrough pain in cancer patients.

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	Fentanyl Citrate Nasal Spray (FCNS)

Timeline

• Start date: 2014-10-01
• Primary completion: 2017-04-01
• Completion: 2018-04-01
• First posted: 2013-04-25
• Last updated: 2018-03-05

Locations

1 site across 1 country: United States